Genetic Technologies Limited (ASX:GTG – Get Rating) insider Jerzy (George) Muchnicki sold 38,400,000 shares of the stock in a transaction that occurred on Monday, January 30th. The stock was sold at an average price of A$0.00 ($0.00), for a total transaction of A$38,400.00 ($27,042.25).
Genetic Technologies Stock Performance
The company has a debt-to-equity ratio of 3.97, a quick ratio of 3.72 and a current ratio of 3.86.
Get
Genetic Technologies alerts:
About Genetic Technologies
(Get Rating)
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate.
See Also
- 2023 Consumer Lending Study – Trends, Statistics, and Forecast
- Here's the Silver Lining with Snap Stock Earnings Collapse
- Mullen Automotive Stock, The Tide Has Turned
- Is BigBear.ai Stock a Diamond in the Rough?
- Apple: What's The Post-Earnings Play?
Receive News & Ratings for Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
Genetic Technologies Limited (ASX:GTG – Get Rating) insider Jerzy (George) Muchnicki sold 38,400,000 shares of the stock in a transaction that occurred on Monday, January 30th. The stock was sold at an average price of A$0.00 ($0.00), for a total transaction of A$38,400.00 ($27,042.25).
遗传技术有限公司（ASX: GTG — GET Rating）内部人士Jerzy（George）Muchnicki在1月30日星期一进行的一笔交易中出售了该股38,400,000股。该股以0.00澳元（0.00美元）的平均价格出售，总交易额为38,400.00澳元（27,042.25美元）。
Genetic Technologies Stock Performance
The company has a debt-to-equity ratio of 3.97, a quick ratio of 3.72 and a current ratio of 3.86.
该公司的债务与权益比率为3.97，速动比率为3.72，流动比率为3.86。
Get
Genetic Technologies
alerts:
About Genetic Technologies
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate.
Genetic Technologies Limited是一家分子诊断公司，提供预测性基因检测和风险评估工具，帮助医生管理美国、加拿大、欧洲、中东、非洲、拉丁美洲和亚太地区的人们的健康。它分两个部门运营，easyDNA和Genetype/Corporate。
See Also
- 2023 Consumer Lending Study – Trends, Statistics, and Forecast
- Here's the Silver Lining with Snap Stock Earnings Collapse
- Mullen Automotive Stock, The Tide Has Turned
- Is BigBear.ai Stock a Diamond in the Rough?
- Apple: What's The Post-Earnings Play?
- 2023 年消费者贷款研究——趋势、统计和预测
- 这是 Snap 股票收益暴跌的一线希望
- 马伦汽车股票，潮流已经转向
- BigBear.ai Stock 是 Rough 中的钻石吗？
- 苹果：财报后的剧情是什么？
Receive News & Ratings for Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
接收《遗传技术日报》的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收有关遗传技术及相关公司的最新新闻和分析师评级的简要每日摘要。
